Loading...

Purified anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_Pure_040912
C57BL/6 mouse bone marrow cells were stained with purified Ly-6G/Ly-6C (clone RB6-8C5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC. Data shown was gated on myeloid cell population.
  • RB6-8C5_Pure_040912
    C57BL/6 mouse bone marrow cells were stained with purified Ly-6G/Ly-6C (clone RB6-8C5) (filled histogram) or rat IgG2b, κ isotype control (open histogram), followed by anti-rat IgG FITC. Data shown was gated on myeloid cell population.
Cat # Size Price Quantity Check Availability Save
108401 50 µg 24 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108402 500 µg 99 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The Ly-6G/Ly-6C antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IP, IHC, WB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Ritchie N, Ijaz U, and Evans T. 2017. BMC Genomics.. 10.1186/s12864-017-4215-3. PubMed
  2. Hawila E, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.104. PubMed
  3. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
  4. Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed
  5. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
  6. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  7. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  8. Ronkina N, et al. 2019. J Immunol. 203:2291. PubMed
  9. McCormick B, et al. 2019. J Immunol. 203:1579. PubMed
  10. Sparber F et al. 2019. British journal of pharmacology. 176(11):1728-1744 . PubMed
  11. Dave K et al. 2017. eLife. 6 pii: e23382. PubMed
  12. He X, et al. 2017. Cancer Biol Ther. 0.815277778. PubMed
  13. Telford W, et al. 2017. Cytometry A. 91:314. PubMed
  14. Rios–Doria J, et al. 2017. Cancer Res. 77:2686. PubMed
  15. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  16. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  17. Parigi SM, et al. 2018. Sci Rep. 0.440277778. PubMed
  18. Cao Q, et al. 2018. Am J Physiol Renal Physiol. 314:F561. PubMed
  19. Wicki S, et al. 2018. Int J Mol Sci. 1.266666667. PubMed
  20. Pushalkar S, et al. 2018. Cancer Discov. 0.613194444. PubMed
  21. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
  22. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  23. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  24. Chen S, et al. 2018. Immunohorizons. 0.345138889. PubMed
  25. Hwang BJ, et al. 2019. Oncogene. 38:7491. PubMed
  26. Nederhoff MGJ, et al. 2019. Auton Neurosci. 221:102580. PubMed
  27. Wolf Y, et al. 2017. J Exp Med. 214:905. PubMed
  28. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
  29. Zhang J, et al. 2019. Onco Targets Ther. 12:4985. PubMed
  30. Shao Y, et al. 2017. Onco Targets Ther. 10:2675. PubMed
  31. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  32. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  33. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  34. Umemoto T, et al. 2017. EMBO J. 36:2390. PubMed
  35. Gautam J, et al. 2020. J Neuroinflammation. 17:103. PubMed
  36. Mainini F, et al. 2018. Nucleic Acid Ther. 28:225. PubMed
  37. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  38. Hameed AM, et al. 2020. Sci Rep. 5.229166667. PubMed
  39. Satoh–Takayama N, et al. 2020. Immunity. 52(4):635-649. PubMed
  40. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  41. Matsuno Y, et al. 2007. Am J Respir Crit Care Med. 176:1015. PubMed
  42. Arnold S, et al. 2008. Exp Biol Med. 233:860. PubMed
  43. Piao Y, et al. 2012. Neuro Oncology. 14:1379. PubMed
  44. Mori H, et al. 2015. Toxicol Pathol. 43: 883-889. PubMed
  45. Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed
  46. Artz A, Butz S, Vestweber D 2016. Am J Physiol Renal Physiol. 311: F176 - F181. PubMed
  47. Weidner H, et al. 2020. JCI Insight. 5:00. PubMed
  48. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
  49. Bernal S, et al. 2020. British Journal of Pharmacology. 178(3):564-581. PubMed
  50. Wang SS, et al. 2021. Cell Chemical Biology. 28(5):699-710.e5. PubMed
  51. Heib T, et al. 2021. Cell Reports. 35(6):109102. PubMed
  52. Lopez-Sanz L, et al. 2021. Clinical and Translational Medicine. 11(7):e463. PubMed
  53. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  54. Wu Y, et al. 2020. Biol Reprod. 1213:102. PubMed
  55. Pérez-Hernández M, et al. 2021. Front Physiol. 11:623190. PubMed
  56. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  57. Joseph R, et al. 2021. Br J Cancer. 125:176. PubMed
  58. Zalacain M, et al. 2021. Mol Ther Oncolytics. 20:23. PubMed
  59. Ren AQ, et al. 2021. Front Pharmacol. 12:693298. PubMed
  60. Nguyen N, et al. 2022. iScience. 25:103679. PubMed
  61. Ruiz-Fernandez de Cordoba B, et al. 2022. Cancer Discov. . PubMed
  62. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  63. Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed
  64. Yang M, et al. 2020. Oncoimmunology. 9:1708064. PubMed
  65. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  66. Lin Z, et al. 2021. Stem Cells. 39:240. PubMed
  67. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  68. Ramirez-Moral I, et al. 2021. J Pathol. 253:374. PubMed
  69. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
  70. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  71. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  72. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  73. Wang H, et al. 2021. Nat Commun. 12:4826. PubMed
  74. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  75. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
  76. Yang J, et al. 2022. Biosci Rep. :. PubMed
  77. Bogorodskiy AO, et al. 2020. Front Immunol. 11:298. PubMed
  78. Schuler CF, et al. 2020. Allergy. 75:2279. PubMed
  79. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  80. Peng V, et al. 2020. J Biol Chem. 295:14866. PubMed
  81. Nguyen CH, et al. 2020. Biomedicines. 8:. PubMed
  82. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  83. Dubik M, et al. 2021. Front Neurosci. 15:682451. PubMed
  84. Jin H, et al. 2021. Int J Mol Sci. 22:. PubMed
  85. Zhang P, et al. 2022. Nat Commun. 13:1588. PubMed
  86. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  87. Malinczak CA, et al. 2021. J Immunol. 206:1315. PubMed
  88. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  89. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  90. Li L, et al. 2023. Br J Pharmacol. 180:287. PubMed
  91. Ruiz-Fernández de Córdoba B, et al. 2022. Cancer Discov. 12:1356. PubMed
  92. Shirai T, et al. 2022. Cancer Sci. 113:3710. PubMed
RRID
AB_313366 (BioLegend Cat. No. 108401)
AB_313367 (BioLegend Cat. No. 108402)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org
Go To Top Version: 3    Revision Date: 11.19.2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account